-
1
-
-
0020068317
-
A native 170, 000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles
-
Cohen S, Ushiro H, Stoscheck C, Chinkers M. A native 170, 000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J Biol Chem 1982, 257:1523-1531.
-
(1982)
J Biol Chem
, vol.257
, pp. 1523-1531
-
-
Cohen, S.1
Ushiro, H.2
Stoscheck, C.3
Chinkers, M.4
-
2
-
-
0024442943
-
The epidermal growth factor receptor tyrosine kinase in liver epithelial cells. The effect of ligand-dependent changes in cellular location
-
McCune BK, Earp HS. The epidermal growth factor receptor tyrosine kinase in liver epithelial cells. The effect of ligand-dependent changes in cellular location. J Biol Chem 1989, 264:15501-15507.
-
(1989)
J Biol Chem
, vol.264
, pp. 15501-15507
-
-
McCune, B.K.1
Earp, H.S.2
-
3
-
-
18644370411
-
Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha
-
10.1016/S0092-8674(02)00940-6, 12297049
-
Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu HJ, Walker F, Frenkel MJ, Hoyne PA, et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 2002, 110:763-773. 10.1016/S0092-8674(02)00940-6, 12297049.
-
(2002)
Cell
, vol.110
, pp. 763-773
-
-
Garrett, T.P.1
McKern, N.M.2
Lou, M.3
Elleman, T.C.4
Adams, T.E.5
Lovrecz, G.O.6
Zhu, H.J.7
Walker, F.8
Frenkel, M.J.9
Hoyne, P.A.10
-
4
-
-
18644386251
-
Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains
-
10.1016/S0092-8674(02)00963-7, 12297050
-
Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002, 110:775-787. 10.1016/S0092-8674(02)00963-7, 12297050.
-
(2002)
Cell
, vol.110
, pp. 775-787
-
-
Ogiso, H.1
Ishitani, R.2
Nureki, O.3
Fukai, S.4
Yamanaka, M.5
Kim, J.H.6
Saito, K.7
Sakamoto, A.8
Inoue, M.9
Shirouzu, M.10
Yokoyama, S.11
-
5
-
-
0036632368
-
The phosphatidylinositol 3-Kinase AKT pathway in human cancer
-
10.1038/nrc839, 12094235
-
Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501. 10.1038/nrc839, 12094235.
-
(2002)
Nat Rev Cancer
, vol.2
, pp. 489-501
-
-
Vivanco, I.1
Sawyers, C.L.2
-
6
-
-
0032881288
-
AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation
-
10.1146/annurev.biochem.68.1.965, 10872470
-
Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 1999, 68:965-1014. 10.1146/annurev.biochem.68.1.965, 10872470.
-
(1999)
Annu Rev Biochem
, vol.68
, pp. 965-1014
-
-
Chan, T.O.1
Rittenhouse, S.E.2
Tsichlis, P.N.3
-
7
-
-
0028040812
-
Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor
-
359038, 7518560
-
Batzer AG, Rotin D, Urena JM, Skolnik EY, Schlessinger J. Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Biol 1994, 14:5192-5201. 359038, 7518560.
-
(1994)
Mol Cell Biol
, vol.14
, pp. 5192-5201
-
-
Batzer, A.G.1
Rotin, D.2
Urena, J.M.3
Skolnik, E.Y.4
Schlessinger, J.5
-
8
-
-
0026729382
-
The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling
-
10.1016/0092-8674(92)90167-B, 1322798
-
Lowenstein EJ, Daly RJ, Batzer AG, Li W, Margolis B, Lammers R, Ullrich A, Skolnik EY, Bar-Sagi D, Schlessinger J. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 1992, 70:431-442. 10.1016/0092-8674(92)90167-B, 1322798.
-
(1992)
Cell
, vol.70
, pp. 431-442
-
-
Lowenstein, E.J.1
Daly, R.J.2
Batzer, A.G.3
Li, W.4
Margolis, B.5
Lammers, R.6
Ullrich, A.7
Skolnik, E.Y.8
Bar-Sagi, D.9
Schlessinger, J.10
-
9
-
-
40849147041
-
EGFR antagonists in cancer treatment
-
10.1056/NEJMra0707704, 18337605
-
Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008, 358:1160-1174. 10.1056/NEJMra0707704, 18337605.
-
(2008)
N Engl J Med
, vol.358
, pp. 1160-1174
-
-
Ciardiello, F.1
Tortora, G.2
-
10
-
-
34547410311
-
Cellular responses to EGFR inhibitors and their relevance to cancer therapy
-
10.1016/j.canlet.2007.02.006, 1986742, 17367921
-
Dutta PR, Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 2007, 254:165-177. 10.1016/j.canlet.2007.02.006, 1986742, 17367921.
-
(2007)
Cancer Lett
, vol.254
, pp. 165-177
-
-
Dutta, P.R.1
Maity, A.2
-
11
-
-
0036164390
-
Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer
-
10.1023/A:1013397232011, 11859875
-
Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 2002, 71:67-75. 10.1023/A:1013397232011, 11859875.
-
(2002)
Breast Cancer Res Treat
, vol.71
, pp. 67-75
-
-
Tsutsui, S.1
Ohno, S.2
Murakami, S.3
Hachitanda, Y.4
Oda, S.5
-
12
-
-
23944476155
-
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
-
10.1200/JCO.2005.16.584, 15955900
-
Burris HA, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005, 23:5305-5313. 10.1200/JCO.2005.16.584, 15955900.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5305-5313
-
-
Burris, H.A.1
Hurwitz, H.I.2
Dees, E.C.3
Dowlati, A.4
Blackwell, K.L.5
O'Neil, B.6
Marcom, P.K.7
Ellis, M.J.8
Overmoyer, B.9
Jones, S.F.10
-
13
-
-
20244388653
-
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
-
10.1200/JCO.2005.12.157, 15684311
-
Spector NL, Xia W, Burris H, Hurwitz H, Dees EC, Dowlati A, O'Neil B, Overmoyer B, Marcom PK, Blackwell KL, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005, 23:2502-2512. 10.1200/JCO.2005.12.157, 15684311.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2502-2512
-
-
Spector, N.L.1
Xia, W.2
Burris, H.3
Hurwitz, H.4
Dees, E.C.5
Dowlati, A.6
O'Neil, B.7
Overmoyer, B.8
Marcom, P.K.9
Blackwell, K.L.10
-
14
-
-
38749087923
-
Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study
-
10.1016/j.ejca.2007.12.011, 18249110
-
Twelves C, Trigo JM, Jones R, De Rosa F, Rakhit A, Fettner S, Wright T, Baselga J. Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. Eur J Cancer 2008, 44:419-426. 10.1016/j.ejca.2007.12.011, 18249110.
-
(2008)
Eur J Cancer
, vol.44
, pp. 419-426
-
-
Twelves, C.1
Trigo, J.M.2
Jones, R.3
De Rosa, F.4
Rakhit, A.5
Fettner, S.6
Wright, T.7
Baselga, J.8
-
15
-
-
33745277110
-
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
-
2361320, 16685276
-
Ciardiello F, Troiani T, Caputo F, De Laurentiis M, Tortora G, Palmieri G, De Vita F, Diadema MR, Orditura M, Colantuoni G, et al. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 2006, 94:1604-1609. 2361320, 16685276.
-
(2006)
Br J Cancer
, vol.94
, pp. 1604-1609
-
-
Ciardiello, F.1
Troiani, T.2
Caputo, F.3
De Laurentiis, M.4
Tortora, G.5
Palmieri, G.6
De Vita, F.7
Diadema, M.R.8
Orditura, M.9
Colantuoni, G.10
-
16
-
-
23944464495
-
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer
-
10.1200/JCO.2005.08.326, 15939921
-
Baselga J, Albanell J, Ruiz A, Lluch A, Gascon P, Guillem V, Gonzalez S, Sauleda S, Marimon I, Tabernero JM, et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005, 23:5323-5333. 10.1200/JCO.2005.08.326, 15939921.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5323-5333
-
-
Baselga, J.1
Albanell, J.2
Ruiz, A.3
Lluch, A.4
Gascon, P.5
Guillem, V.6
Gonzalez, S.7
Sauleda, S.8
Marimon, I.9
Tabernero, J.M.10
-
17
-
-
0036848757
-
Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer
-
Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J, Hachitanda Y. Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res 2002, 8:3454-3460.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 3454-3460
-
-
Tsutsui, S.1
Kataoka, A.2
Ohno, S.3
Murakami, S.4
Kinoshita, J.5
Hachitanda, Y.6
-
18
-
-
20044381463
-
Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation
-
10.1111/j.1349-7006.2005.00009.x, 15649255
-
Tsuda H, Morita D, Kimura M, Shinto E, Ohtsuka Y, Matsubara O, Inazawa J, Tamaki K, Mochizuki H, Tamai S, Hiraide H. Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. Cancer Sci 2005, 96:48-53. 10.1111/j.1349-7006.2005.00009.x, 15649255.
-
(2005)
Cancer Sci
, vol.96
, pp. 48-53
-
-
Tsuda, H.1
Morita, D.2
Kimura, M.3
Shinto, E.4
Ohtsuka, Y.5
Matsubara, O.6
Inazawa, J.7
Tamaki, K.8
Mochizuki, H.9
Tamai, S.10
Hiraide, H.11
-
19
-
-
0032927489
-
Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas
-
10.1023/A:1006194700667, 10326794
-
Walker RA, Dearing SJ. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat 1999, 53:167-176. 10.1023/A:1006194700667, 10326794.
-
(1999)
Breast Cancer Res Treat
, vol.53
, pp. 167-176
-
-
Walker, R.A.1
Dearing, S.J.2
-
20
-
-
13844317894
-
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
-
10.1056/NEJMoa044238, 15728811
-
Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792. 10.1056/NEJMoa044238, 15728811.
-
(2005)
N Engl J Med
, vol.352
, pp. 786-792
-
-
Kobayashi, S.1
Boggon, T.J.2
Dayaram, T.3
Janne, P.A.4
Kocher, O.5
Meyerson, M.6
Johnson, B.E.7
Eck, M.J.8
Tenen, D.G.9
Halmos, B.10
-
21
-
-
18244371651
-
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
-
10.1371/journal.pmed.0020073, 549606, 15737014
-
Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73. 10.1371/journal.pmed.0020073, 549606, 15737014.
-
(2005)
PLoS Med
, vol.2
-
-
Pao, W.1
Miller, V.A.2
Politi, K.A.3
Riely, G.J.4
Somwar, R.5
Zakowski, M.F.6
Kris, M.G.7
Varmus, H.8
-
22
-
-
77349124901
-
EGFR mutations and the terminal respiratory unit
-
10.1007/s10555-010-9205-8, 20135199
-
Yatabe Y. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev 2010, 29:23-36. 10.1007/s10555-010-9205-8, 20135199.
-
(2010)
Cancer Metastasis Rev
, vol.29
, pp. 23-36
-
-
Yatabe, Y.1
-
23
-
-
33750302365
-
Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib
-
10.1158/1078-0432.CCR-06-0714, 17020982
-
Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, Tada H, Kuwano H, Mitsudomi T. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006, 12:5764-5769. 10.1158/1078-0432.CCR-06-0714, 17020982.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 5764-5769
-
-
Kosaka, T.1
Yatabe, Y.2
Endoh, H.3
Yoshida, K.4
Hida, T.5
Tsuboi, M.6
Tada, H.7
Kuwano, H.8
Mitsudomi, T.9
-
24
-
-
33751292685
-
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
-
10.1158/1078-0432.CCR-06-1570, 17085664
-
Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006, 12:6494-6501. 10.1158/1078-0432.CCR-06-1570, 17085664.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 6494-6501
-
-
Balak, M.N.1
Gong, Y.2
Riely, G.J.3
Somwar, R.4
Li, A.R.5
Zakowski, M.F.6
Chiang, A.7
Yang, G.8
Ouerfelli, O.9
Kris, M.G.10
-
25
-
-
58149333768
-
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma
-
10.1158/1078-0432.CCR-08-0151, 2596620, 19010870
-
Bean J, Riely GJ, Balak M, Marks JL, Ladanyi M, Miller VA, Pao W. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 2008, 14:7519-7525. 10.1158/1078-0432.CCR-08-0151, 2596620, 19010870.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 7519-7525
-
-
Bean, J.1
Riely, G.J.2
Balak, M.3
Marks, J.L.4
Ladanyi, M.5
Miller, V.A.6
Pao, W.7
-
26
-
-
33749435816
-
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
-
10.1172/JCI28656, 1570180, 16906227
-
Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borras AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 2006, 116:2695-2706. 10.1172/JCI28656, 1570180, 16906227.
-
(2006)
J Clin Invest
, vol.116
, pp. 2695-2706
-
-
Engelman, J.A.1
Mukohara, T.2
Zejnullahu, K.3
Lifshits, E.4
Borras, A.M.5
Gale, C.M.6
Naumov, G.N.7
Yeap, B.Y.8
Jarrell, E.9
Sun, J.10
-
27
-
-
56449089812
-
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations
-
10.1158/0008-5472.CAN-08-1643, 19010923
-
Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008, 68:9479-9487. 10.1158/0008-5472.CAN-08-1643, 19010923.
-
(2008)
Cancer Res
, vol.68
, pp. 9479-9487
-
-
Yano, S.1
Wang, W.2
Li, Q.3
Matsumoto, K.4
Sakurama, H.5
Nakamura, T.6
Ogino, H.7
Kakiuchi, S.8
Hanibuchi, M.9
Nishioka, Y.10
-
28
-
-
65949086609
-
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR
-
10.1158/0008-5472.CAN-08-4055, 2849653, 19351834
-
Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009, 69:3256-3261. 10.1158/0008-5472.CAN-08-4055, 2849653, 19351834.
-
(2009)
Cancer Res
, vol.69
, pp. 3256-3261
-
-
Sos, M.L.1
Koker, M.2
Weir, B.A.3
Heynck, S.4
Rabinovsky, R.5
Zander, T.6
Seeger, J.M.7
Weiss, J.8
Fischer, F.9
Frommolt, P.10
-
29
-
-
70149110218
-
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones
-
2745674, 19794967
-
Marchetti A, Milella M, Felicioni L, Cappuzzo F, Irtelli L, Del Grammastro M, Sciarrotta M, Malatesta S, Nuzzo C, Finocchiaro G, et al. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia 2009, 11:1084-1092. 2745674, 19794967.
-
(2009)
Neoplasia
, vol.11
, pp. 1084-1092
-
-
Marchetti, A.1
Milella, M.2
Felicioni, L.3
Cappuzzo, F.4
Irtelli, L.5
Del Grammastro, M.6
Sciarrotta, M.7
Malatesta, S.8
Nuzzo, C.9
Finocchiaro, G.10
-
30
-
-
58149149814
-
Epidermal growth factor receptor mutations in small cell lung cancer
-
10.1158/1078-0432.CCR-08-0332, 18829487
-
Tatematsu A, Shimizu J, Murakami Y, Horio Y, Nakamura S, Hida T, Mitsudomi T, Yatabe Y. Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 2008, 14:6092-6096. 10.1158/1078-0432.CCR-08-0332, 18829487.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 6092-6096
-
-
Tatematsu, A.1
Shimizu, J.2
Murakami, Y.3
Horio, Y.4
Nakamura, S.5
Hida, T.6
Mitsudomi, T.7
Yatabe, Y.8
-
31
-
-
33745913034
-
EGFR mutations in small-cell lung cancers in patients who have never smoked
-
10.1056/NEJMc053610, 16837691
-
Zakowski MF, Ladanyi M, Kris MG. EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 2006, 355:213-215. 10.1056/NEJMc053610, 16837691.
-
(2006)
N Engl J Med
, vol.355
, pp. 213-215
-
-
Zakowski, M.F.1
Ladanyi, M.2
Kris, M.G.3
-
32
-
-
33646864481
-
EGFR mutation in gefitinib-responsive small-cell lung cancer
-
10.1093/annonc/mdj114, 16357019
-
Okamoto I, Araki J, Suto R, Shimada M, Nakagawa K, Fukuoka M. EGFR mutation in gefitinib-responsive small-cell lung cancer. Ann Oncol 2006, 17:1028-1029. 10.1093/annonc/mdj114, 16357019.
-
(2006)
Ann Oncol
, vol.17
, pp. 1028-1029
-
-
Okamoto, I.1
Araki, J.2
Suto, R.3
Shimada, M.4
Nakagawa, K.5
Fukuoka, M.6
-
33
-
-
77957572836
-
[TNM classification of breast cancer: changes and comments on the 7th edition]
-
10.1007/s00292-010-1307-0, 20711589
-
Sinn HP, Helmchen B, Wittekind CH. [TNM classification of breast cancer: changes and comments on the 7th edition]. Pathologe 2010, 31:361-366. 10.1007/s00292-010-1307-0, 20711589.
-
(2010)
Pathologe
, vol.31
, pp. 361-366
-
-
Sinn, H.P.1
Helmchen, B.2
Wittekind, C.H.3
-
34
-
-
79960980007
-
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
-
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736-1747.
-
Ann Oncol
, vol.22
, pp. 1736-1747
-
-
Goldhirsch, A.1
Wood, W.C.2
Coates, A.S.3
Gelber, R.D.4
Thurlimann, B.5
Senn, H.J.6
-
35
-
-
57749118336
-
Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer
-
10.1186/bcr2128, 2575540, 18681955
-
Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 2008, 10:R67. 10.1186/bcr2128, 2575540, 18681955.
-
(2008)
Breast Cancer Res
, vol.10
-
-
Tamimi, R.M.1
Baer, H.J.2
Marotti, J.3
Galan, M.4
Galaburda, L.5
Fu, Y.6
Deitz, A.C.7
Connolly, J.L.8
Schnitt, S.J.9
Colditz, G.A.10
Collins, L.C.11
-
36
-
-
40949121882
-
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype
-
10.1158/1078-0432.CCR-07-1658, 18316557
-
Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008, 14:1368-1376. 10.1158/1078-0432.CCR-07-1658, 18316557.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 1368-1376
-
-
Cheang, M.C.1
Voduc, D.2
Bajdik, C.3
Leung, S.4
McKinney, S.5
Chia, S.K.6
Perou, C.M.7
Nielsen, T.O.8
-
37
-
-
0031822837
-
Tissue microarrays for high-throughput molecular profiling of tumor specimens
-
10.1038/nm0798-844, 9662379
-
Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4:844-847. 10.1038/nm0798-844, 9662379.
-
(1998)
Nat Med
, vol.4
, pp. 844-847
-
-
Kononen, J.1
Bubendorf, L.2
Kallioniemi, A.3
Barlund, M.4
Schraml, P.5
Leighton, S.6
Torhorst, J.7
Mihatsch, M.J.8
Sauter, G.9
Kallioniemi, O.P.10
-
38
-
-
73349140213
-
EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer
-
10.1136/jcp.2009.066548, 2771853, 19861557
-
Varella-Garcia M, Diebold J, Eberhard DA, Geenen K, Hirschmann A, Kockx M, Nagelmeier I, Ruschoff J, Schmitt M, Arbogast S, Cappuzzo F. EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J Clin Pathol 2009, 62:970-977. 10.1136/jcp.2009.066548, 2771853, 19861557.
-
(2009)
J Clin Pathol
, vol.62
, pp. 970-977
-
-
Varella-Garcia, M.1
Diebold, J.2
Eberhard, D.A.3
Geenen, K.4
Hirschmann, A.5
Kockx, M.6
Nagelmeier, I.7
Ruschoff, J.8
Schmitt, M.9
Arbogast, S.10
Cappuzzo, F.11
-
39
-
-
20444498630
-
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
-
10.1093/jnci/dji112, 15870435
-
Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005, 97:643-655. 10.1093/jnci/dji112, 15870435.
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 643-655
-
-
Cappuzzo, F.1
Hirsch, F.R.2
Rossi, E.3
Bartolini, S.4
Ceresoli, G.L.5
Bemis, L.6
Haney, J.7
Witta, S.8
Danenberg, K.9
Domenichini, I.10
-
40
-
-
0142119289
-
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis
-
10.1200/JCO.2003.11.069, 12953099
-
Hirsch FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21:3798-3807. 10.1200/JCO.2003.11.069, 12953099.
-
(2003)
J Clin Oncol
, vol.21
, pp. 3798-3807
-
-
Hirsch, F.R.1
Varella-Garcia, M.2
Bunn, P.A.3
Di Maria, M.V.4
Veve, R.5
Bremmes, R.M.6
Baron, A.E.7
Zeng, C.8
Franklin, W.A.9
-
41
-
-
58149343564
-
Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers
-
10.1186/1471-2407-8-309, 2612006, 18950515
-
Toyama T, Yamashita H, Kondo N, Okuda K, Takahashi S, Sasaki H, Sugiura H, Iwase H, Fujii Y. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. BMC Cancer 2008, 8:309. 10.1186/1471-2407-8-309, 2612006, 18950515.
-
(2008)
BMC Cancer
, vol.8
, pp. 309
-
-
Toyama, T.1
Yamashita, H.2
Kondo, N.3
Okuda, K.4
Takahashi, S.5
Sasaki, H.6
Sugiura, H.7
Iwase, H.8
Fujii, Y.9
-
42
-
-
33644539850
-
Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay
-
10.1016/j.lungcan.2005.08.009, 16199108
-
Endo K, Konishi A, Sasaki H, Takada M, Tanaka H, Okumura M, Kawahara M, Sugiura H, Kuwabara Y, Fukai I, et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 2005, 50:375-384. 10.1016/j.lungcan.2005.08.009, 16199108.
-
(2005)
Lung Cancer
, vol.50
, pp. 375-384
-
-
Endo, K.1
Konishi, A.2
Sasaki, H.3
Takada, M.4
Tanaka, H.5
Okumura, M.6
Kawahara, M.7
Sugiura, H.8
Kuwabara, Y.9
Fukai, I.10
-
43
-
-
0023949462
-
Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma
-
Ro J, North SM, Gallick GE, Hortobagyi GN, Gutterman JU, Blick M. Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma. Cancer Res 1988, 48:161-164.
-
(1988)
Cancer Res
, vol.48
, pp. 161-164
-
-
Ro, J.1
North, S.M.2
Gallick, G.E.3
Hortobagyi, G.N.4
Gutterman, J.U.5
Blick, M.6
-
44
-
-
9244222241
-
Prognostic relevance of gene amplifications and coamplifications in breast cancer
-
10.1158/0008-5472.CAN-04-1945, 15574759
-
Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Kochli O, et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004, 64:8534-8540. 10.1158/0008-5472.CAN-04-1945, 15574759.
-
(2004)
Cancer Res
, vol.64
, pp. 8534-8540
-
-
Al-Kuraya, K.1
Schraml, P.2
Torhorst, J.3
Tapia, C.4
Zaharieva, B.5
Novotny, H.6
Spichtin, H.7
Maurer, R.8
Mirlacher, M.9
Kochli, O.10
-
45
-
-
24044520039
-
EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations
-
10.1038/modpathol.3800438, 15920544
-
Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 2005, 18:1027-1033. 10.1038/modpathol.3800438, 15920544.
-
(2005)
Mod Pathol
, vol.18
, pp. 1027-1033
-
-
Bhargava, R.1
Gerald, W.L.2
Li, A.R.3
Pan, Q.4
Lal, P.5
Ladanyi, M.6
Chen, B.7
-
46
-
-
2942629610
-
Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma
-
10.1038/labinvest.3700077, 15031710
-
Kersting C, Tidow N, Schmidt H, Liedtke C, Neumann J, Boecker W, van Diest PJ, Brandt B, Buerger H. Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma. Lab Invest 2004, 84:582-587. 10.1038/labinvest.3700077, 15031710.
-
(2004)
Lab Invest
, vol.84
, pp. 582-587
-
-
Kersting, C.1
Tidow, N.2
Schmidt, H.3
Liedtke, C.4
Neumann, J.5
Boecker, W.6
van Diest, P.J.7
Brandt, B.8
Buerger, H.9
-
47
-
-
42249105872
-
Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy
-
10.1158/1535-7163.MCT-07-0570, 2745608, 18413808
-
Gilbert JA, Goetz MP, Reynolds CA, Ingle JN, Giordano KF, Suman VJ, Blair HE, Jenkins RB, Lingle WL, Reinholz MM, et al. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol Cancer Ther 2008, 7:944-951. 10.1158/1535-7163.MCT-07-0570, 2745608, 18413808.
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 944-951
-
-
Gilbert, J.A.1
Goetz, M.P.2
Reynolds, C.A.3
Ingle, J.N.4
Giordano, K.F.5
Suman, V.J.6
Blair, H.E.7
Jenkins, R.B.8
Lingle, W.L.9
Reinholz, M.M.10
-
48
-
-
84925550146
-
Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis
-
10.1186/bcr1341, 1410747, 16280056
-
Reis-Filho JS, Milanezi F, Carvalho S, Simpson PT, Steele D, Savage K, Lambros MB, Pereira EM, Nesland JM, Lakhani SR, Schmitt FC. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res 2005, 7:R1028-1035. 10.1186/bcr1341, 1410747, 16280056.
-
(2005)
Breast Cancer Res
, vol.7
-
-
Reis-Filho, J.S.1
Milanezi, F.2
Carvalho, S.3
Simpson, P.T.4
Steele, D.5
Savage, K.6
Lambros, M.B.7
Pereira, E.M.8
Nesland, J.M.9
Lakhani, S.R.10
Schmitt, F.C.11
-
49
-
-
33748653109
-
Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas
-
10.1200/JCO.2006.07.2587, 16943533
-
Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, Jarrett C, Carter J, Murphy BA, Netterville J, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006, 24:4170-4176. 10.1200/JCO.2006.07.2587, 16943533.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4170-4176
-
-
Chung, C.H.1
Ely, K.2
McGavran, L.3
Varella-Garcia, M.4
Parker, J.5
Parker, N.6
Jarrett, C.7
Carter, J.8
Murphy, B.A.9
Netterville, J.10
-
50
-
-
34250155320
-
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer
-
10.1200/JCO.2006.06.6605, 17538160
-
Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, Liu DD, Lang W, Issa JP, Lee JJ, Mao L. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007, 25:2164-2170. 10.1200/JCO.2006.06.6605, 17538160.
-
(2007)
J Clin Oncol
, vol.25
, pp. 2164-2170
-
-
Temam, S.1
Kawaguchi, H.2
El-Naggar, A.K.3
Jelinek, J.4
Tang, H.5
Liu, D.D.6
Lang, W.7
Issa, J.P.8
Lee, J.J.9
Mao, L.10
-
51
-
-
33846444010
-
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing
-
10.1634/theoncologist.12-1-90, 17285735
-
Sequist LV, Joshi VA, Janne PA, Muzikansky A, Fidias P, Meyerson M, Haber DA, Kucherlapati R, Johnson BE, Lynch TJ. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist 2007, 12:90-98. 10.1634/theoncologist.12-1-90, 17285735.
-
(2007)
Oncologist
, vol.12
, pp. 90-98
-
-
Sequist, L.V.1
Joshi, V.A.2
Janne, P.A.3
Muzikansky, A.4
Fidias, P.5
Meyerson, M.6
Haber, D.A.7
Kucherlapati, R.8
Johnson, B.E.9
Lynch, T.J.10
-
52
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
10.1056/NEJMoa040938, 15118073
-
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139. 10.1056/NEJMoa040938, 15118073.
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
Gurubhagavatula, S.4
Okimoto, R.A.5
Brannigan, B.W.6
Harris, P.L.7
Haserlat, S.M.8
Supko, J.G.9
Haluska, F.G.10
-
53
-
-
2342624080
-
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
-
10.1126/science.1099314, 15118125
-
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500. 10.1126/science.1099314, 15118125.
-
(2004)
Science
, vol.304
, pp. 1497-1500
-
-
Paez, J.G.1
Janne, P.A.2
Lee, J.C.3
Tracy, S.4
Greulich, H.5
Gabriel, S.6
Herman, P.7
Kaye, F.J.8
Lindeman, N.9
Boggon, T.J.10
-
54
-
-
4444344330
-
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
-
10.1073/pnas.0405220101, 516528, 15329413
-
Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101:13306-13311. 10.1073/pnas.0405220101, 516528, 15329413.
-
(2004)
Proc Natl Acad Sci USA
, vol.101
, pp. 13306-13311
-
-
Pao, W.1
Miller, V.2
Zakowski, M.3
Doherty, J.4
Politi, K.5
Sarkaria, I.6
Singh, B.7
Heelan, R.8
Rusch, V.9
Fulton, L.10
-
55
-
-
19944427851
-
Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer
-
Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, Peyton M, Juroske D, Huang Y, Stuart Salmon J, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005, 65:226-235.
-
(2005)
Cancer Res
, vol.65
, pp. 226-235
-
-
Amann, J.1
Kalyankrishna, S.2
Massion, P.P.3
Ohm, J.E.4
Girard, L.5
Shigematsu, H.6
Peyton, M.7
Juroske, D.8
Huang, Y.9
Stuart Salmon, J.10
-
56
-
-
10844231985
-
Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications
-
10.1158/0008-5472.CAN-04-2818, 15604253
-
Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004, 64:8919-8923. 10.1158/0008-5472.CAN-04-2818, 15604253.
-
(2004)
Cancer Res
, vol.64
, pp. 8919-8923
-
-
Kosaka, T.1
Yatabe, Y.2
Endoh, H.3
Kuwano, H.4
Takahashi, T.5
Mitsudomi, T.6
|